Dear Friends,

Today, March 30, is Doctors' Day, a day of recognition that began in 1933 to honor the dedication and care provided by physicians and clinicians. This year, we owe extra-special thanks to the NET specialists who have worked above and beyond their calling during the COVID pandemic. 

Let's recognize the NET specialists who sacrificed so much in the past year to keep us safe and healthy. With your online donation, NETRF will notify the physician or provider who has made a difference in your life with a letter of gratitude and a certificate. Your gift will support vital NET research into better treatments for neuroendocrine cancer. NETRF will celebrate Doctors’ Day through the month of April, providing time to donate and applaud your NET specialist.

This effort last year resulted in such heartfelt responses from the NET community. I encourage you to join me in honoring your physician for Doctors' Day 2021 and support NETRF at the same time. Show your support and appreciation by applauding your health care hero.

Elyse Gellerman, 
NETRF Chief Executive Officer

Building a Friendship and a Foundation to Fight NETs

Anne Doyle received news that no daughter wants to hear in 1993. Her father Hugh had carcinoid tumors in his liver and lungs. As a result of his diagnosis, Anne was introduced to a cancer and a world that she never expected. Just over a decade later, that world included Nancy Lindholm, a 29-year-old tax attorney who had recently been diagnosed with metastatic neuroendocrine cancer.  Continue Reading Anne’s Story (CONTINUE READING)

NETRF Receives Record Number of Research Proposals

The 2021 NETRF Grant Award Program received a record 102 applications that were well distributed across the four award types and across the spectrum of basic, translational and clinical research. Applications were received from 22 countries reflecting the expanding global NET research community and NETRF’s growing support of international NET research. The applications have been assigned to be reviewed by NETRF’s 24-member review committee whose broad collective expertise ensures that only the most transformational NET research will be selected to receive funding. NETRF represents the single largest private funder of NET research.

A Look Inside the Clark Lab at UCLA

In January, NETRF announced a Pilot Award to Peter M. Clark, PhD of the UCLA Crump Institute for Molecular Imaging for his research of pancreatic NETs. The award was made possible by Katherine Mueller NET Research Fund. Katherine is a pancreatic NET patient and NETRF donor who hosted fundraisers in 2019 and 2020. In late February, Katherine found herself hospitalized facing a serious health scare resulting from her NETs. When Peter and his team learned about her condition, they worked with NETRF to create a video to wish her well and show her the science she is making possible.

We are pleased to report that Katherine is recovering and growing stronger by the day. With her permission, we’d like to share the video with you. Whether you are interested in a behind-the-scenes tour of the lab, understanding the science that could result in new therapies for pNETs or to see first-hand the commitment NET researchers have to patients, we think you’ll find this video to be meaningful. (WATCH VIDEO)

A Moment of Gratitude and a Warm Welcome
NETRF Announces Leadership Changes to the Board of Scientific Advisors

It is with gratitude and profound respect that The Neuroendocrine Tumor Research Foundation (NETRF) announces Dan Chung, MD will be stepping down from his role as the co-chair of our Board of Scientific Advisors (BOSA) to serve as a member and that Dawn E. Quelle, PhD, from the Holden Comprehensive Cancer Center at the University of Iowa College of Medicine will take his place.
“It has been a distinct privilege and honor to serve on the BOSA,” said Chung.  “It has been particularly gratifying to see the tremendous impact that NETRF-funded research has had on the field in a relatively short time period.”

To learn more about their contributions to NETRF, read our blog post. (CONTINUE READING)

NETRF Is Making a Global Footprint in the Fight Against Neuroendocrine Cancers

NETRF continues to build a global community of researchers as scientists from around the world recognize they are eligible to apply for NETRF research grants. Over the last two years, NETRF has awarded nine awards to international researchers. This is a number that is expected to continue growing. 

We credit growing awareness of NETRF among the international research community, in part, to our collaboration with the European Neuroendocrine Tumor Society (ENETS), which recently held its 18th annual conference. NETRF was proud to both participate in and support this educational effort aimed at improving the diagnosis and treatment of NETs. (LEARN MORE)

Apply now for $100,000 Nuclear Medicine Pilot Research Grant

The call for applications for a $100,000 Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors has been extended to April 2, 2021. The Neuroendocrine Tumor Research Foundation is pleased to partner with the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) to offer this research opportunity. The award is designed to help a basic or clinical scientist in the early stages of his/her career conduct novel and innovative research that may be leveraged to lead to further funding from other foundations, corporations or government agencies. (LEARN MORE)

A Clinical Research Study Explores the Use of a Photodynamic Therapy to Target NET cells

Martin Gotthardt, PhD, of Radboud University in the Netherlands is leading an international collaboration between researchers in Spain and the Netherlands to explore the use of photodynamic therapy to target NET cells. Gotthardt received a NETRF Investigator Award in 2019.

Currently, the only option to cure patients with NETs is through the complete removal of the tumor(s) with surgery. However, there remains the risk of residual cells that can allow the cancer to come back. Gotthardt and his team are working to develop molecules that could aid a surgeon in removing all the tumor cells by using an approach called tumor targeted photodynamic therapy. In this therapy, a molecule called a photosensitizer is delivered to the tumor cells where it binds and is activated with near infrared light (using a LED or a laser). Upon activation, the photosensitizer would produce molecules called reactive oxygen species (ROS) which are toxic to cells and would thus induce tumor cell death.

Gotthardt describes the team’s progress, “With the funding that we received from NETRF, we were able to join forces between chemists and medical biologists, to develop novel photosensitizers for implementation in a promising treatment strategy named targeted photodynamic therapy. Besides using these photosensitizers for targeting two well-known targets in neuroendocrine tumors (GLP1R and SSTR2), they can easily be used for coupling to other molecules in future projects, expanding the therapeutic repertoire for neuroendocrine tumors or other cancer types.”

NEW NETWise Podcast: NETs and Genetic Screening

What role do genetics play in neuroendocrine tumors? Is genetic screening right for you? In this episode of NETWise, we’ll explore the role DNA plays in NETS and why your genetic code might hold important implications for treatment strategies and the health of family members. (LISTEN NOW) 

Colorectal Cancer Awareness Month

It may be the last day of March, but awareness for cancers of the intestines and rectum should extend throughout the year. NETs of the gastrointestinal (GI) tract have an incidence rate of 3.65 per 100,000 people.
NETRF offers several resources for patients. To better understand how GI NETs occur and how they progress, we invite you to watch a presentation from our video library by Thor R. Halfdanarson, MD, Professor of Medical Oncology at the Mayo Clinic in Rochester, MN.

For those of you living with small bowel NETs, you can learn more about how they grow, treatments options and the latest research in our Special NETWise Podcast Episode: Small Bowel NETs.




Doctor Database   Patient Groups
Newly Diagnosed   About NETs
Facebook Twitter
Contact Us

NET Research Foundation
31 St. James Avenue, Suite 365
Boston, MA 02116

(617) 946-1780 |
The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.
powered by emma
Subscribe to our email list.